ELIGIBILITY CRITERIA

The National Institute for Health and Clinical Excellence (NICE) has recommended that all psoriasis patients in the UK should be registered with us. The following is our eligibility criteria:

- Patient must be starting or switching to one of these drugs, for treatment of their psoriasis, in the last 6 months to be eligible for our conventional, biologic or small molecule cohorts:
  - Acitretin
  - Ciclosporin
  - Fumaric acid esters
  - Hydroxycarbamide
  - Methotrexate
  - Oral PUVA
  - Amgevita (Adalimumab biosimilar)
  - BenePali (Etanercept biosimilar)
  - Cimzia (Certolizumab pegol)
  - Cosentyx (Secukinumab)
  - Erelzi (Etanercept biosimilar)
  - Hyrimoz (Adalimumab biosimilar)
  - Ilumetri (tildrakizumab)
  - Imraldi (Adalimumab biosimilar)
  - Kyntheum (Brodalumab)
  - Taltz (Ixekizumab)
  - Tremfya (Guselkumab)
  - Zessly (Infliximab biosimilar)
  - Skilarence (dimethyl fumarate)

- Conventional patients must have a PASI of 10 or more and a DLQI of 11 or more (unless switching between conventional therapies). There is no minimum score for biologic or small molecule patients (but we still require a PASI and DLQI).

- Patients entering either the small molecule or conventional cohorts must be naive to biologic therapy.

TREATMENTS

Patient must be starting or switching to one of these drugs, for treatment of their psoriasis, in the last 6 months to be eligible for our conventional, biologic or small molecule cohorts: